BIOMAT Database Logo BIOMAT Database Logo

Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine. 1998

E Snoeck, and K Ver Donck, and P Jacqmin, and H Van Belle, and A G Dupont, and A Van Peer, and M Danhof
Department of Clinical Pharmacokinetics, Janssen Research Foundation, Beerse, Belgium.

A physiological red blood cell (RBC) kinetic model is proposed for the adenosine (ADO) transport into erythrocytes and its subsequent intracellular deamination into inactive inosine (INO) and further breakdown into hypoxanthine (HYPO). The model and its parameters were based on previous studies investigating the kinetics of the biochemical mechanism of uptake and metabolism of ADO in human erythrocytes. Application of the model for simulations of the breakdown of ADO in a RBC suspension revealed that the predicted adenosine breakdown inhibition (ABI) of draflazine corresponded well with the ABI measured ex vivo. The model definitely explained the apparent discrepancy between the ex vivo measured ABI and the nucleoside transporter occupancy of draflazine. Intracellular deamination of ADO rather than its transport by the nucleoside transporter is the rate-limiting step in the overall catabolism of ADO. Consequently, at least 90% occupancy of the transporter by draflazine is required to inhibit adenosine breakdown ex vivo substantially. Simulations on basis of the validated model were performed to evaluate the ABI for different experimental conditions and to mimic the clinical situation. The latter may be very helpful for the design of optimal dosing schemes of draflazine. It was demonstrated that the short half-life of released ADO was prolonged substantially in a dose-related manner after a continuous infusion of draflazine. Finally, the previously found different sigmoidal Emax relationships between the measured ABI and the concentrations of draflazine in plasma and whole blood could be explained by the ADO transport and breakdown RBC kinetic model and the capacity-limited specific RBC binding characteristics of draflazine.

UI MeSH Term Description Entries
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D033703 Nucleoside Transport Proteins Proteins involved in the transport of NUCLEOSIDES across cellular membranes. Nucleoside Transporter,Transport Proteins, Nucleoside,Transporter, Nucleoside

Related Publications

E Snoeck, and K Ver Donck, and P Jacqmin, and H Van Belle, and A G Dupont, and A Van Peer, and M Danhof
Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.
May 1994, British journal of pharmacology,
E Snoeck, and K Ver Donck, and P Jacqmin, and H Van Belle, and A G Dupont, and A Van Peer, and M Danhof
Nucleoside transport inhibition and platelet aggregation in human blood: R75231 and its enantiomers, draflazine and R88016.
January 1994, European journal of pharmacology,
E Snoeck, and K Ver Donck, and P Jacqmin, and H Van Belle, and A G Dupont, and A Van Peer, and M Danhof
Sites of the physiological breakdown of the red blood corpuscles.
March 1958, Nature,
E Snoeck, and K Ver Donck, and P Jacqmin, and H Van Belle, and A G Dupont, and A Van Peer, and M Danhof
Simple model can explain self-inhibition of red cell anion exchange.
January 1985, Biophysical journal,
E Snoeck, and K Ver Donck, and P Jacqmin, and H Van Belle, and A G Dupont, and A Van Peer, and M Danhof
Affinity, binding kinetics and functional characterization of draflazine analogues for human equilibrative nucleoside transporter 1 (SLC29A1).
February 2020, Biochemical pharmacology,
E Snoeck, and K Ver Donck, and P Jacqmin, and H Van Belle, and A G Dupont, and A Van Peer, and M Danhof
Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity.
April 2000, Naunyn-Schmiedeberg's archives of pharmacology,
E Snoeck, and K Ver Donck, and P Jacqmin, and H Van Belle, and A G Dupont, and A Van Peer, and M Danhof
Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations.
January 1997, European journal of clinical pharmacology,
E Snoeck, and K Ver Donck, and P Jacqmin, and H Van Belle, and A G Dupont, and A Van Peer, and M Danhof
Human red-blood-cell Ca2+-antagonist binding sites. Evidence for an unusual receptor coupled to the nucleoside transporter.
July 1985, European journal of biochemistry,
E Snoeck, and K Ver Donck, and P Jacqmin, and H Van Belle, and A G Dupont, and A Van Peer, and M Danhof
Airway compliance and dynamics explain the apparent discrepancy in length adaptation between intact airways and smooth muscle strips.
January 2016, Respiratory physiology & neurobiology,
E Snoeck, and K Ver Donck, and P Jacqmin, and H Van Belle, and A G Dupont, and A Van Peer, and M Danhof
Does higher red blood cell (RBC) lactate transporter activity explain impaired RBC deformability in sickle cell trait?
December 2005, The Japanese journal of physiology,
Copied contents to your clipboard!